World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
69015
World Ranking
5420
National Ranking
535

Overview

Mahesh K. B. Parmar is affiliated with University College London in the United Kingdom, focusing primarily on medical research. Their work spans several main fields and subfields, indicating a concentration on areas related to oncology and clinical trials.

The main field of study associated with Parmar's work is Medicine, with a total of 231 publications. Within this broad field, their subfields of study include:

  • Pulmonary and Respiratory Medicine (85 publications)
  • Statistics and Probability (52 publications)
  • Oncology (34 publications)
  • Radiology, Nuclear Medicine and Imaging (22 publications)
  • Reproductive Medicine (19 publications)

Parmar has explored various key topics in their research, notably:

  • Prostate Cancer Treatment and Research (88 publications)
  • Statistical Methods in Clinical Trials (66 publications)
  • Prostate Cancer Diagnosis and Treatment (42 publications)
  • Ovarian cancer diagnosis and treatment (32 publications)
  • Health Systems, Economic Evaluations, Quality of Life (30 publications)
  • Cancer Genomics and Diagnostics (24 publications)
  • Radiopharmaceutical Chemistry and Applications (22 publications)

Their recent publications include the following works, which have appeared in established medical journals:

  • "Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial," 2021, The Lancet
  • "A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19," 2020, New England Journal of Medicine
  • "Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial," 2020, The Lancet
  • "Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data," 2020, The Lancet
  • "Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis," 2021, The Lancet Regional Health - Europe

Frequent co-authors collaborating with Parmar include:

  • Matthew R. Sydes (46 joint publications)
  • Noel W. Clarke (43 joint publications)
  • Nicholas D. James (39 joint publications)
  • Gerhardt Attard (26 joint publications)
  • Adrian Cook (19 joint publications)

The primary publication venues for Parmar's work are journals that focus on oncology and clinical trial research. These include:

  • Journal of Clinical Oncology (15 publications)
  • The Lancet Oncology (9 publications)
  • Annals of Oncology (9 publications)
  • Trials (7 publications)
  • Clinical Trials (7 publications)

Best Publications

  • Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

    Mahesh K. B. Parmar;Valter Torri;Lesley Stewart

  • Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

    Hashim U Ahmed;Hashim U Ahmed;Ahmed El-Shater Bosaily;Ahmed El-Shater Bosaily;Louise C. Brown;Rhian Gabe

  • A phase 3 trial of bevacizumab in ovarian cancer.

    Timothy J Perren;Ann Marie Swart;Jacobus Pfisterer;Jonathan A Ledermann

  • Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

    David Sebag-Montefiore;Richard J. Stephens;Robert Steele;John Monson

  • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Nicholas D. James;Johann S. de Bono;Melissa R. Spears;Noel W. Clarke

  • Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.

    Patrick Royston;Mahesh K. B. Parmar

  • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Nicholas D. James;Nicholas D. James;Matthew R. Sydes;Noel W. Clarke;Malcolm David Mason

  • Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

    Phil Quirke;Phil Quirke;Robert Steele;John Monson;Robert Grieve

  • Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

    Sean Kehoe;Jane Hook;Matthew Nankivell;Gordon C Jayson

  • Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.

    Ian J Jacobs;Ian J Jacobs;Ian J Jacobs;Usha Menon;Andy Ryan;Aleksandra Gentry-Maharaj

  • International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

    Gareth Griffiths;Reginald Hall;Richard Sylvester;Derek Raghavan

  • Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

    Christopher C Parker;Nicholas D James;Christopher D Brawley;Noel W Clarke

  • Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

    Patrick Royston;Mahesh K B Parmar

  • Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

    David P Dearnaley;Matthew R Sydes;John D Graham;Edwin G Aird

  • Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials

    Claire Vale;Jayne F. Tierney;Lesley A. Stewart;Mark Brady

  • Survival Analysis: A Practical Approach

    David Machin;Yin Bun Cheung;Mahesh K. B. Parmar

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial

    Michele Saunders;Stanley Dische;Ann Barrett;Angela Harvey

  • Bayesian Approaches to Randomized Trials

    David J. Spiegelhalter;Laurence S. Freedman;Mahesh K. B. Parmar

  • Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: Results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)

    Usha Menon;Aleksandra Gentry-Maharaj;Rachel Hallett;Andy Ryan

Frequent Co-Authors

Matthew R. Sydes
Matthew R. Sydes University College London
Nicholas D. James
Nicholas D. James Institute of Cancer Research
Noel W. Clarke
Noel W. Clarke University of Salford
Malcolm David Mason
Malcolm David Mason Cardiff University
Ian Jacobs
Ian Jacobs University of New South Wales
David P. Dearnaley
David P. Dearnaley Institute of Cancer Research
Patrick Royston
Patrick Royston University College London
Chris Parker
Chris Parker Institute of Cancer Research
Usha Menon
Usha Menon University College London
Stephen W. Duffy
Stephen W. Duffy Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medical careers in the USA isn’t limited to becoming a doctor—numerous online degree pathways are available for those seeking flexible options. Registered nurses can upgrade their credentials through rn to bsn programs, which often offer coursework with minimal or no on-site clinical requirements, making them accessible for working professionals.

Those aiming for leadership or advanced practice roles may consider pursuing the shortest dnp programs online, which provide a compact curriculum focused on quick completion. There are even shortest dnp program options designed for efficiency, ideal for nurses eager to achieve a terminal degree without a lengthy time commitment.

For individuals starting their careers, fast track medical programs such as Licensed Practical Nurse (LPN) routes enable entry into the healthcare workforce in less time—using a flexible online format. These related pathways provide modern, efficient alternatives for advancing or starting a medical career in the USA.

Best Scientists Citing Mahesh K. B. Parmar

Trending Scientists